• Haemonetics posted Q1 fiscal 2027 GAAP net income of $33 million, down 2.94% year over year; GAAP EPS rose to $0.72 from $0.70.
• GAAP revenue climbed 5.6% to $339.4 million; Apheresis increased 5.3% to $191.3 million, MedSurg rose 6% to $148.1 million.
• GAAP operating income rose 6.68% to $57.5 million, while the GAAP net income margin narrowed 0.9 percentage points to 9.7%.
• Non-GAAP adjusted EPS increased 3.64% to $1.14, while non-GAAP adjusted operating margin slipped 0.7 percentage points to 23.4%.
• Full-year fiscal 2027 organic revenue growth outlook was raised to 4%-7%, while free cash flow conversion guidance stayed near 80%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Haemonetics Corporation published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.